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Editorial comment
Microarray analysis to evaluate different animal models
for human heart failure
The inability of either or both sides of the heart to pump
sufficient blood for maintenance of body functions is consid-
ered as heart failure (HF). Mutations in several genes have
been associated with HF. Other prominent causes are hyper-
tension, coronary atherosclerosis and rheumatic heart dis-
ease. The use of different animal systems to model cardiovas-
cular disease is important because research on many genetic
and chronic diseases of man cannot be carried out in human
beings. During the last 15 years, the mouse has become the
model organism of choice to study human heart disease for
several reasons (e.g. 99% of the human genes have direct
orthologs in the mouse and gene targeting technology in
mouse embryonic stem cells allows the design and genera-
tion of transgenic mice to model human genetic disorders).
To evaluate the clinical potential of the pathways and net-
works affected in mouse models, parallel studies in larger
animals (e.g. dogs or pigs) are crucial. However, it is essen-
tial to take into account that there are significant differences
between human HF and its animal models.
Numerous genetically engineered mouse models for human
cardiomyopathies have been generated. For some of them an
analogous mutation has been reported to cause human dis-
ease (e.g. MLP, a-MHC) whereas for others this has not been
shown so far (e.g. ErbB2). Indeed, mice show a different
response to drug treatment (e.g. a smaller dynamic range in
cardiac output alterations after adrenergic stimulation) and
have significantly different myocardial action potential wave-
forms than larger animals or human beings [1]. In addition,
one has to consider that in comparison to mouse inbred strains,
due to the polygenic and multifactorial character of human
disease, clinical parameters of patients are highly hetero-
genic. Moreover, it remains unclear whether a specific ani-
mal model resembles the human pathophysiological condi-
tion with its corresponding chronic features like fibrosis,
inflammation, apoptosis and its duration of several years (e.g.
the tachycardia-induced canine model develops HF already
within a few weeks). Nevertheless, the analysis of animal
models allows a better understanding of human disease
mechanisms. Until now, animal models for HF were charac-
terized to a limited extent at phenotypic and biochemical lev-
els. Relevant studies included only a reduced number of
parameters (e.g. BNP plasma levels). Gao and collaborators
tackled this issue with a very innovative and promising
approach. They aimed at the characterization of different ani-
mal models for HF from a global point of view, i.e. at a tran-
scriptional level using a broad gene expression profiling
approach. Therefore they compared the gene expression pat-
tern in a canine HF model with those in human and murine
HF to provide insight for the general validity of their findings
in mammals.
During HF multiple pathways are responsible for trans-
ducing mechanical load and biochemical signals into changes
of gene expression. The molecular basis, i.e. the origins and
mechanisms of many alterations found in patients suffering
from HF is poorly understood, but genome-wide gene expres-
sion analysis approaches are starting to reveal important asso-
ciations between gene expression signatures and the patho-
genesis and outcome of the disease [2–4]. High expectations
have been raised that expression profiles might be used as a
diagnostic and/or prognostic aid in disease management, e.g.
before and after left ventricular assist device placement [5].
Moreover, recent reports based on expression profiling data
demonstrate the feasibility of discrimination between differ-
ent disease entities, e.g. ischemic and non-ischemic cardi-
omyopathy [6] or disease stages [7].
The report by Gao and collaborators is the first one on the
comparison of gene expression profiles of a canine tachycar-
dia pacing-induced HF model and human and murine HF.
The authors used the human 20K cDNA microarray fabri-
cated by the Microarray Core of the John Hopkins University
to measure the gene expression of the left and right ventricles
from normal and failing age-matched male canine hearts. The
ventricle-specific expression profiles as well as the healthy
and disease-specific ones were obtained and compared with
those from human HF patients and from two different mouse
models for HF. The authors aimed at the identification of glo-
bal processes associated with HF instead of focusing on indi-
vidual genes and compared their overlap between different
human etiologies and different animal models. Therefore, dif-
ferential gene expression was detected using the significance
analysis of microarrays (SAM; Tusher et al.) and a subse-
quent expression analysis systematic explorer (EASE) was
applied to the data set to identify gene ontology (GO) catego-
ries with an overrepresented number of deregulated genes.
GO annotation represents a powerful tool to encounter the
challenge of long lists of deregulated genes. It provides first
hints on the affected pathways or processes and has been suc-
cessfully applied to numerous data sets during the last few
years. Using this approach the authors could correlate sev-
eral GO categories, e.g. nucleic acid metabolism, transcrip-
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tion and energy pathways with HF in the canine tachycardia-
induced model. The majority of deregulated genes was found
in the failing left ventricle whereas no significant overrepre-
sentation of genes in distinct GO categories between the ven-
tricles was found. It seems surprising, however, that in con-
trast to other studies (mainly using human samples), a high
percentage (95%) of the genes with significant expression dif-
ferences were found to be down-regulated and no induction
of prominent HF markers, e.g. ANP and BNP was detected.
The authors’ main interest was to evaluate the similarities
and differences of the transcriptional program between the
animal models and that in human HF. For obvious reasons a
gene-by-gene comparison of lists of deregulated HF-
associated genes derived from different species is neither con-
clusive nor meaningful. In a comparable and exemplary study,
Lee et al. [8] used hierarchical clustering and several
expression-based prediction methods to identify the best-fit
mouse model for hepatocellular carcinomas [8]. Samples of
seven different mouse models (68 animals in total) were com-
pared with 91 human samples grouped in a better and a poorer
survival group, respectively. Here, a strong correlation was
found between Myc, E2f1 and Myc-E2f1 transgenic mice and
the patients of the better survival group, whereas Myc-TGFa
transgenic mice and diethylnitrosamine-treated animals were
most similar to the poorer survival group of patients (Fig. 1).
Notably, the authors could validate and substantiate their find-
ings using the human poorer and better survival groups as
training sets for supervised expression-based classification:
again a strong correlation of Myc-TGFa transgenic mice with
the poorer survival group of patients was found. Altogether,
unsupervised (clustering) and supervised (expression-based
classification) methods allowed the identification of mouse
models mimicking best different human cancer disease enti-
ties. Such approaches however are restricted to calculated
expression similarities and do not directly deliver informa-
tion about the global biological processes involved.
Gao and co-workers tackled this issue and used EASE to
identify GO categories being that they were mainly affected
during HF in the different species. Their own generated data
from the canine tachycardia pacing-induced model was com-
pared with that of human ischemic and idiopathic etiologies
as well as with two different mouse models, the TNFa over-
expression model and the MLP knockout model. Human
expression data were downloaded from the website of Car-
diogenomics (http://www.cardiogenomics.med.harvard.edu)
and mouse expression data were obtained from previously
reported studies [9,10]. Surprisingly, the authors found only
little overlap in the GO categories between the different ani-
mal models analyzed and human HF. It is noteworthy that out
of the 18 GO categories characteristic for the canine HF
model, eight of them were identical in the human ischemic
HF group. Notably, the GO categories found (e.g. immune
and defense response, antigen presentation and chemotaxis)
in the specific animal models (e.g. the TNFa transgenic mice)
appear to be model- and pathway-specific suggesting that mul-
tiple molecular mechanisms may converge on a HF pheno-
type.
Cross-species hybridization was proven earlier to facili-
tate the identification of differentially expressed ortholog
genes in tissues derived from different species [11]. This
approach has therefore become acceptable and very reason-
able for species for which no array format is available. Indeed,
Gao et al. confirmed the differential expression of several
genes detected in cross-species hybridizations (canine tar-
gets onto human probes) with RT-PCR demonstrating the
validity of their experimental setting. It seems difficult how-
ever to estimate the false positive and especially the false nega-
tive rate of the approach in comparison to species-matching
expression profiling experiments. This issue becomes rel-
evant when comparing the canine tachycardia-induced model
array data with the mouse model and human HF array data,
since specific binding of the probe and the target on the
microarray depends on their sequence similarity. Variations
in the sequence conservation of genes belonging to different
GO categories (i.e. immune response or the TCA cycle) might
in such an experimental setting lead to GO category-specific
false negative rates.
Another key issue in this regard is that the array data ana-
lyzed here were generated by independent research groups
Fig. 1. Dendogram of an unsupervised cluster analysis of integrated 68 mouse and 91 human hepatocellular carcinoma (HCC) samples based on 1650 ortho-
logous genes. Red and blue bars represent human and mouse HCC tissues, human samples are subdivided into a poorer (Cluster A (Hs)) and a better survival
group ((Cluster B (Hs)). Adapted from [8].
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using different microarray platforms (i.e. Affymetrix and
in-house produced arrays). As reported in several studies
expression profiling of the same biological material but using
different array platforms delivers data sets with alarmingly
poor overlap [12] (Fig. 2). This outcome originates mainly
from a high false negative rate caused by, e.g. differences in
sensitivity and in the targeted sequences. These effects,
together with the biological heterogeneity of the samples used,
become apparent in several published array studies on HF
[2,3,13,14]. In these data sets only a limited overlap of deregu-
lated genes can be found and the deregulation of even promi-
nent HF markers belonging to the fetal gene program, e.g.
ANP, BNP or alpha skeletal actin cannot be reproducibly
detected.
Altogether, Gao et al., conclude that the comparison among
the canine tachypacing, mouse transgenic and human HF
reveals that human HF involves deregulation of genes in a
broad range of biological processes and that chronically devel-
oping human HF may impact more biological processes than
the experimentally induced genetic of sub-acute HF models.
The identification of animal models for human disease in gen-
eral and HF in particular which may serve as valuable experi-
mental systems for an improved diagnosis and treatment of
human HF remains a challenge. It can however certainly be
assisted by comparing comprehensive gene expression pat-
terns of different animal models with those of human patients.
The study by Gao et al. provides insights into the molecular
pathways leading to HF and into global transcriptional dif-
ferences between animal models for HF and human HF dem-
onstrating that the careful and detailed analysis of global gene
expression patterns between different animal models and
across species may be instrumental.
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Fig. 2. Venn diagram with the differentially expressed genes detected by
gene expression profiling using the same biological material but three diffe-
rent platforms with five replicates for each platform: Amersham (Codelink
Uniset Human 1), Agilent (Agilent Human 1 cDNA array) and Affymetrix
(U95A v2). Note the small overlap of deregulated genes identified using the
different platforms. Adapted from [12].
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